A Premier Medical Center Is Self-Funding A (Nasdaq: VBIO) Trial (News Dropped This Week)

Here is something that does not come along often.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored A Premier Medical Center Is Self-Funding A (Nasdaq: VBIO) Trial (News Dropped This Week) *Click Here To Get Our Alerts Faster Via SMS* July 22nd Dear Reader, Here is something that does not come along often. A biopharmaceutical company that designed its lead drug for one of the rarest and most harrowing scenarios imaginable, a nuclear or radiological mass-casualty event, is now watching that same drug get pulled in an entirely different direction: keeping cancer patients alive through their own treatment. That is the story behind Valion Bio (Nasdaq: VBIO). The San Antonio, Texas-based company spent years developing Entolimod, a TLR5 agonist that switches on the body's innate immune system through a receptor pathway embedded in the gut lining. The target was Acute Radiation Syndrome. Over $140Mn has gone into this drug's development across its history, with $35.6Mn of that arriving as non-dilutive federal funding. For a long time, nobody outside of national security circles was paying much attention. That could be starting to change. In May 2026, CEO Michael K. Handley walked into a joint briefing with senior officials from the U.S. Department of War and BARDA for the second time in consecutive months. The officials did not just listen. They asked specifically about an oral formulation of Entolimod. That question carries meaning. Then, in July 2026, Sheba Medical Center announced it would independently fund and conduct a clinical trial studying Entolimod in cancer patients undergoing high-dose radiation therapy. Sheba contacted Valion Bio. They are paying for it themselves. Two things happened in that single development. Entolimod's clinical utility expanded beyond the defense world. And VBIO gained external scientific validation it did not need to fund. With a share float of approximately 2.56Mn shares, VBIO sits in a category where the potential for heightened volatility may exist on daily business. The question worth asking is: what potential catalysts are already in motion? Valion Bio, Inc. (Nasdaq: VBIO) describes itself as a clinical-stage biopharmaceutical company, and the description holds up to scrutiny. Entolimod is not in early trials. It has been through 42 non-human primate studies and evaluated in approximately 300 human subjects. It carries both FDA Fast Track designation and Orphan Drug designation. It is advancing under the FDA's Animal Rule pathway, the regulatory mechanism used when human efficacy trials are neither ethically nor practically feasible. That is precisely the situation for a drug designed to treat mass radiation exposure. The company's second molecule, Entolasta, is a next-generation TLR5 agonist designed for sustained use in oncology supportive care and immune aging applications. It is positioned for the patient population that chemotherapy and radiation therapy create: people whose immune systems are temporarily decimated by the very treatments designed to save them. TLR5 Platform: Large Market Opp. $330Bn+ Combined Addressable Market Across Four Immunology Verticals From Biodefense To Oncology Supportive Care In December 2025, Valion Bio acquired Velocity Bioworks and opened its fully operational biomanufacturing facility in San Antonio in May 2026. The facility employs approximately 45 scientists, engineers, and operators and has already demonstrated a 200-fold scale-up of Entolimod production, achieving 50-liter fermentation capacity representing approximately 1.3Mn potential human doses. The CDMO also actively pursues third-party biomanufacturing contracts. At the same time, VBIO's oncology play is accelerating. The AFRRI and NIAID designed a proprietary PBI-BM2.5 protocol specifically to evaluate Entolimod for gastrointestinal ARS, a segment with no currently approved or stockpiled countermeasure. NIAID is fully funding the work and co-navigating the FDA submission. That structure, the government paying for the science and guiding the filing, is not a standard development arrangement for a company of VBIO's size. As of Q1 2026, VBIO reported $7.2Mn in cash on hand. NIAID's up to $7Mn in non-dilutive federal funding now covers all remaining in vivo studies on the BLA critical path, and the agency will co-navigate the FDA submission when favorable data arrive. 7 Potential Catalysts Pin (Nasdaq: VBIO) To Our Wednesday Watchlist 1.) A Float Of Approximately 2.56Mn Shares Means The Environment For Heightened Volatility May Exist Daily. At the time of this writing, VBIO's share float sits at approximately 2.56Mn shares, qualifying it as a low float name where the potential for heightened volatility may be significant, particularly if government procurement or clinical news flow accelerates around its pipeline. 2.) AFRRI And NIAID Designed A Proprietary Protocol Specifically To Advance VBIO's GI-ARS Program. The PBI-BM2.5 protocol was built from the ground up to evaluate Entolimod as a potential first-and-only treatment for gastrointestinal ARS, a segment with no approved or stockpiled countermeasure, under an FDA Animal Rule-compatible design that leverages a previously FDA-accepted protocol structure. 3.) Two Pentagon Briefings In Two Months Suggest Momentum Inside Government On VBIO's Platform. VBIO briefed Pentagon leadership in April 2026 and returned for a second joint session with senior Department of War and BARDA officials in May 2026. That follow-up meeting, driven by government officials requesting more information, points to escalating internal interest rather than routine engagement. 4.) Velocity Bioworks Provides VBIO A Revenue Stream That Does Not Depend On Drug Approval. VBIO's wholly-owned CDMO subsidiary actively pursues third-party biomanufacturing contracts while anchoring domestic production of Entolimod, building a commercial revenue channel that is structurally independent from clinical or regulatory outcomes and rare for a company at this market capitalization. 5.) Several Oversold Leaning Technicals Could Be Hinting At Reversal Potential A technical analysis reveals VBIO has several oversold indicators, suggesting a possible reversal setup may be developing. At 3:30PM EST on Tuesday, VBIO had a 9-Day and 14-Day Relative Strength Index both below 27% and a 9-Day and 14-Day Raw Stochastic below 4%. These technical levels suggest a profile that may be currently undervalued. 6.) FDA Fast Track And Orphan Drug Designations Shorten VBIO's Potential Timeline To Review. Both designations were awarded to Entolimod and provide rolling review eligibility and expedited interaction with the FDA during the BLA process, tools that can meaningfully compress the time between a complete submission and a regulatory decision when favorable animal efficacy data are in hand. 7.) Sheba's Self-Funded Trial Could Generate VBIO's First Human Oncology Data At Zero Cost. Sheba Medical Center's independent decision to self-sponsor a trial studying Entolimod in radiation oncology patients could generate clinical evidence connecting VBIO's TLR5 platform to the multi-Bn-dollar oncology supportive care market, at no expense to the company and with the credibility of an externally driven study design. Final Thoughts Valion Bio, Inc. (Nasdaq: VBIO) is not telling a speculative story. The federal agencies that operate in this space do not schedule repeat briefings with companies that have not done the work. A world-class cancer center does not self-fund a trial with a drug it does not believe in. A government agency does not design a proprietary study protocol for a platform it views as a long shot And a biomanufacturing facility employing 45 scientists is not built on the back of a concept note. The Entolimod story is still being written. But what is already on the page, the government validation, the external clinical partners, the domestic manufacturing base, the legislative tailwind from the FY27 NDAA, and the oncology expansion underway, is enough to make VBIO a name worth keeping close. Coverage is officially initiated on Valion Bio, Inc. (Nasdaq: VBIO). Updates will be heading out soon. Keep your eyes peeled. Sincerely, FierceAnalyst | Jaks Swift Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 07/21/2026 and ending on 07/22/2026 to publicly disseminate information about (VBIO:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). These Funds were part of the forty five thousand USD funds that TD Media LLC received from a third party named Tusk Strategic Communications who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (VBIO:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/vbio-mdg52/#details

Fierce Investor | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice